TIDMAREC
Arecor Therapeutics PLC
04 September 2023
Arecor Therapeutics plc
("Arecor" or the "Group")
TETRIS PHARMA ANNOUNCES COMMERCIALISATION AGREEMENT WITH
GOODLIFE
Cambridge, UK, 4 September 2023: Arecor Therapeutics plc (AIM:
AREC), the biopharmaceutical group advancing today's therapies to
enable healthier lives, announces that subsidiary company, Tetris
Pharma Ltd has established an exclusive commercialisation agreement
with Goodlife, who will act as sole partner for the import,
marketing and distribution of Ogluo(R) in the BeNeLux region.
See full Tetris Pharma announcement below:
Tetris Pharma announces commercialisation agreement with
Goodlife
Partnership to drive accelerated market adoption of Ogluo in
BeNeLux region
4 September 2023 - Tetris Pharma Ltd ("Tetris Pharma" or "the
Company"), a subsidiary of biopharmaceutical company, Arecor
Therapeutics plc (AIM: AREC), today announces that it has
established an exclusive commercialisation agreement with Goodlife,
who will act as sole partner for the import, marketing and
distribution of Ogluo(R) (glucagon prefilled autoinjector pen) in
the BeNeLux region.
The Zorginstiuut Nederland (the National Healthcare Institute of
The Netherlands) has approved Ogluo(R) at the requested price on
List 1B and Goodlife is expected to launch the product in The
Netherlands during H1 2024.
Sarah Howell, Chief Executive Officer at Arecor, said: "Goodlife
provides the commercial expertise and detailed understanding of
regional market dynamics that are essential for the Company's
continued roll-out of Ogluo(R) and its market adoption in the
BeNeLux region. The upcoming launch in The Netherlands adds to
existing markets in the UK, Germany, Austria, Denmark and Norway,
as part of the planned on-going pan-European commercial roll-out
for this important product."
Koen Perenboom, Managing Director, Goodlife, said: "With more
than a quarter of a million people living with insulin-treated
diabetes and at risk of severe hypoglycaemia in The Netherlands,
Ogluo is an important treatment option for people with diabetes and
their caregivers, that can provide them with the confidence to
manage severe hypoglycaemic events. This strategic collaboration
with Arecor symbolises our mutual commitment to provide every
individual patient excellent care."
About Ogluo(R):
Ogluo(R) is a ready-to-use, ambiently stored, preparation of
glucagon in an auto-injector for patients within the licenced
indication living with diabetes suffering from severe
hypoglycaemia(1) . Hypoglycaemia is a common and serious
complication of diabetes, particularly affecting people with
diabetes on insulin treatment. It is characterised by abnormally
low blood sugar levels, which can lead to cognitive impairment and
in some severe cases, seizures, loss of consciousness, coma and
even death. It can have a profound effect on the everyday lives of
people with diabetes and their caregivers(2) . The European
Commission granted the marketing authorization for Ogluo(R) on 11
February 2021.
1. Ogluo SmPC
2. Amiel, S.A. The consequences of hypoglycaemia. Diabetologia 64, 963-970 (2021). https://doi.org/10.1007/s00125-020-05366-3
Notes to Editors
Tetris Pharma, a subsidiary of Arecor Therapeutics plc, is a
commercial-stage specialty pharmaceutical company with expertise in
registering, marketing, sales and the distribution of speciality
hospital products across the UK and Europe. Our experienced team
has a proven history of building and growing sales. Having secured
distribution rights for already licensed products across Europe, we
have a portfolio of niche injectable products including Ogluo(R), a
ready-to-use glucagon for emergency use to treat hypoglycaemia. We
collaborate with partners to provide patients with effective
treatments and quality healthcare by ensuring we deliver
accountability, partnership and performance. For further
information, please visit www.tetrispharma.com .
Goodlife is a privately owned pharmaceutical company with a
focus on The Netherlands, Belgium and Luxembourg. Goodlife believes
that every patient deserves excellent care that matches their
individual needs, even if those needs deviate from the norm. With
this in mind, we strive for customization every day, by providing
unique medicines, medical devices, dietary supplements and
supportive tools for individual patients in the BeNeLux. For more
information, please visit www.goodlifepharma.com .
-ENDS-
For more information, please contact:
Arecor Therapeutics plc www.arecor.com
Dr Sarah Howell, Chief Executive Tel: +44 (0) 1223 426060
Officer Email: info@arecor.com
Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Mo Noonan, Communications Tel: +44 (0) 7876 444977
Email: mo.noonan@arecor.com
Panmure Gordon (UK) Limited (NOMAD
and Broker)
Freddy Crossley, Emma Earl (Corporate Tel: +44 (0) 20 7886 2500
Finance)
Rupert Dearden (Corporate Broking)
Consilium Strategic Communications
Chris Gardner, David Daley, Lindsey Tel: +44 (0) 20 3709 5700
Neville Email: arecor@consilium-comms.com
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical
group transforming patient care by bringing innovative medicines to
market through the enhancement of existing therapeutic products. By
applying our innovative proprietary formulation technology
platform, Arestat(TM), we are developing an internal portfolio of
proprietary products in diabetes and other indications, as well as
working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The
Arestat(TM) platform is supported by an extensive patent portfolio.
For further details please see our website, www.arecor.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAUPUBABUPWGMG
(END) Dow Jones Newswires
September 04, 2023 02:00 ET (06:00 GMT)
Grafico Azioni Arecor Therapeutics (LSE:AREC)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Arecor Therapeutics (LSE:AREC)
Storico
Da Set 2023 a Set 2024